IRMD - Company ID 0001325618
The table below shows IRADIMED CORP's income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $21.98M | $21.20M | $20.41M | $19.51M | $18.33M | $17.93M |
| Cost of revenue | $5.17M | $4.71M | $4.45M | $4.67M | $4.13M | $3.92M |
| Gross profit | $16.81M | $16.49M | $15.95M | $14.84M | $14.19M | $14.01M |
| R&D | $956.00K | $674.36K | $877.36K | $624.00K | $639.47K | $801.13K |
IRADIMED CORP reported annual revenue of $83.81M for fiscal year 2025. That is up 14.4% from $73.24M in fiscal 2024. Over the 10 fiscal years shown, annual revenue grew from $32.50M (FY 2016) to $83.81M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A | $4.57M | $4.36M | $4.28M | $4.61M | $3.97M | $4.10M |
| Operating income | $7.24M | $6.83M | $6.79M | $5.43M | $5.79M | $5.63M |
| Income tax | $1.95M | $1.72M | $1.55M | $1.26M | $1.37M | $1.37M |
| Net income | $5.82M | $5.58M | $5.77M | $4.69M | $5.05M | $4.90M |
| EPS (diluted) | $0.45 | $0.43 | $0.45 | $0.37 | $0.40 | $0.38 |